



**Drug Utilization Review Board
Meeting Agenda, Open Session
November 14, 2014 2:00 p.m. – 3:00 p.m.
Meeting Location
HP Enterprise Services, Capital Room
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, KS 66619
Conference Line: 855.795.6874
Conference ID: 27548732**

Board Members

| | |
|--------------------------|----------------------|
| James Backes, PharmD | Russell Scheffer, MD |
| Tim Heston, DO | Kevin Waite, PharmD |
| John Kollhoff, PharmD | Roger Unruh, DO |
| Judy McDaniel Dowd, PA-C | |

KDHE-DHCF Staff

| | |
|------------------------|----------------------|
| F.E. Bustillo, III, MD | Liane Larson, PharmD |
| Kelley Melton, PharmD | |

HP Enterprise Services/HID Staff

| | |
|---------------------------|-------------------------|
| Nicole Ellermeier, PharmD | Karen Kluczykowski, RPh |
| Nancy Perry, RN | |

MCO Staff

Jonalan Smith, PharmD, FASCP, **Sunflower State Health Plan**
Jennifer Murff, RPh, **UnitedHealthcare Community Plan**
Lisa Todd, RPh, **Amerigroup**

I. CALL TO ORDER

A. Announcements

II. OLD BUSINESS

A. Review and Approval of October 8, 2014 Meeting Minutes

III. NEW BUSINESS

A. New Prior Authorization (PA) Criteria

1. Harvoni® (ledipasvir/sofosbuvir)

Harvoni is a recently approved direct acting for the treatment of chronic hepatitis C genotype 1 infection. Prior authorization criteria are being proposed to be in line with other direct acting Hepatitis C agents, the criteria follow the FDA label information and national guidelines for the treatment of chronic hepatitis C to ensure appropriate use.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

IV. OPEN PUBLIC COMMENT

V. ADJOURN

The next DUR Board meeting is scheduled for January 14, 2015.

*Public comment is limited to five minutes per product, per person; additional time will be allowed at the DUR Board's discretion.
Informal comments from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****